REPROCELL Corporate News (3)

We are pleased to announce that on Tuesday 6th April 2021, REPROCELL launched a new testing service for the identification for Covid-19 variants using the Allplex SARS-CoV-2 Variants I Assay...

YOKOHAMA, 22 March, 2021/ REPROCELL has initiated a collaboration with Blacktrace Holdings Ltd in the sales of their Nadia series: a single-cell analytical system, in Japan. Single-cell analysis, or...

YOKOHAMA, March 16, 2021/ We are pleased to announce that our cell processing facility, REPROCELL Regenerative Medicine Center (located in Life Innovation Center in the Kanagawa region), was...

NEW YORK, March 11, 2021/PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a partnership agreement with REPROCELL, a contract research...

Hyderabad India – 11 March 2021: Bioserve Biotechnologies Pvt Ltd, 100% owned subsidiary of REPROCELL Inc, is pleased to announce the launch of Non-Invasive Prenatal Testing (NIPT) services in...

[Glasgow, UK] REPROCELL has contributed to a novel publication detailing advancements in induced pluripotent stem cell (iPSC) reprogramming. The paper, published in New Biotechnology by Dr Amer Rana...

[Yokohama, Japan] REPROCELL will launch a new PCR testing service for COVID-19 from March 2021 in collaboration with DNAFORM Inc: a Japanese start-up company based on cutting-edge technologies...

All patients have been registered at ten sites in Japan for the Phase II clinical trial of Stemchymal®, a human adipose-derived stem cell product exclusively licensed in Japan by Steminent...

[Hyderabad, India] Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced Bioserve Biotechnologies Pvt Ltd (REPROCELL’s 100% owned subsidiary) as the...

17 December 2020 [Japan, Yokohama]: REPROCELL has announced that they will launch a new service to generate individual specific induced pluripotent stem cell (iPSC) in January, “Personal iPS”...

Beltsville, USA: REPROCELL, an industry leader in the use of human biospecimens for medical research, has partnered with Scientist.com, the healthcare industry’s leading marketplace for life science...

Rotterdam, The Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a new collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to...

March 19, 2020 Niel, Belgium, (‘eTheRNA’ or The Company’), a clinical-stage company developing vaccines from its proprietary mRNA TriMix platform, today announced that the consortium it leads with...

Yokahoma, Japan: REPROCELL announce the launch of StemRNA™ Entero: human iPSC-derived intestinal epithelial cells. StemRNA™ Entero cells are intestinal epithelial cells derived from human iPSCs. This...

Yokohama, Japan: REPROCELL is delighted to announce the launch a new service for consumers, Personal iPS, in which induced pluripotent stem cells (iPSCs) re established for future regenerative...

REPROCELL has recently joined an international consortium, led by Belgium company etheRNA, to develop a novel mRNA vaccine against CoV-2. Administered intranasally, the proposed vaccine is intended...

REPROCELL is pleased to announce that the first patient has been registered and the test article administered at Nagoya University in the Phase II clinical trial of the regenerative medicine product...

Dates: 19-20 February 2020 Venue: Copthorne Tara, London, United Kingdom Website: https://www.smi-online.co.uk/pharmaceuticals/uk/3D-Cell-Culture REPROCELL Europe’s CSO Professor Stefan Przyborski...

A recent study by researchers from REPROCELL found that IBD patients display different drug absorption profiles to healthy individuals. This is the first time that drug absorption has been estimated...

Glasgow, UK: REPROCELL (Biopta) today announced that they can predict test article permeability using gastrointestinal (GI) resections from Inflammatory Bowel Disease (IBD) donors. This service,...